Annual Accounts Payable
$606.60 M
+$17.40 M+2.95%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual accounts payable is currently $606.60 million, with the most recent change of +$17.40 million (+2.95%) on 31 December 2023. During the last 3 years, it has risen by +$131.10 million (+27.57%). REGN annual accounts payable is now at all-time high.REGN Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$497.30 M
-$64.40 M-11.47%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly accounts payable is currently $497.30 million, with the most recent change of -$64.40 million (-11.47%) on 30 September 2024. Over the past year, it has dropped by -$39.30 million (-7.32%). REGN quarterly accounts payable is now -25.92% below its all-time high of $671.30 million, reached on 31 March 2024.REGN Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +3.0% | -7.3% |
| 3 y3 years | +27.6% | +16.5% |
| 5 y5 years | +178.0% | +48.2% |
REGN Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +27.6% | -25.9% | +16.5% |
| 5 y | 5 years | at high | +178.0% | -25.9% | +48.2% |
| alltime | all time | at high | >+9999.0% | -25.9% | >+9999.0% |
Regeneron Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $497.30 M(-11.5%) |
| June 2024 | - | $561.70 M(-16.3%) |
| Mar 2024 | - | $671.30 M(+10.7%) |
| Dec 2023 | $606.60 M(+3.0%) | $606.60 M(+13.0%) |
| Sept 2023 | - | $536.60 M(-2.0%) |
| June 2023 | - | $547.30 M(-8.7%) |
| Mar 2023 | - | $599.50 M(+1.7%) |
| Dec 2022 | $589.20 M(+4.5%) | $589.20 M(+10.0%) |
| Sept 2022 | - | $535.60 M(+0.3%) |
| June 2022 | - | $534.20 M(+13.6%) |
| Mar 2022 | - | $470.30 M(-16.6%) |
| Dec 2021 | $564.00 M(+18.6%) | $564.00 M(+32.1%) |
| Sept 2021 | - | $427.00 M(-10.3%) |
| June 2021 | - | $476.00 M(-12.3%) |
| Mar 2021 | - | $542.90 M(+14.2%) |
| Dec 2020 | $475.50 M(+13.7%) | $475.50 M(+7.3%) |
| Sept 2020 | - | $443.10 M(+16.6%) |
| June 2020 | - | $380.10 M(+9.3%) |
| Mar 2020 | - | $347.80 M(-16.8%) |
| Dec 2019 | $418.10 M(+91.6%) | $418.10 M(+24.6%) |
| Sept 2019 | - | $335.60 M(+37.5%) |
| June 2019 | - | $244.00 M(+1.8%) |
| Mar 2019 | - | $239.60 M(+9.8%) |
| Dec 2018 | $218.20 M(+22.4%) | $218.20 M(+26.6%) |
| Sept 2018 | - | $172.36 M(+0.3%) |
| June 2018 | - | $171.91 M(-17.2%) |
| Mar 2018 | - | $207.61 M(+16.5%) |
| Dec 2017 | $178.20 M(+32.0%) | $178.20 M(+15.8%) |
| Sept 2017 | - | $153.95 M(+1.7%) |
| June 2017 | - | $151.37 M(+6.7%) |
| Mar 2017 | - | $141.80 M(+5.1%) |
| Dec 2016 | $134.98 M(-4.2%) | $134.98 M(+8.4%) |
| Sept 2016 | - | $124.50 M(+22.4%) |
| June 2016 | - | $101.72 M(-15.7%) |
| Mar 2016 | - | $120.59 M(-14.4%) |
| Dec 2015 | $140.96 M(+41.7%) | $140.96 M(+31.8%) |
| Sept 2015 | - | $106.92 M(-17.8%) |
| June 2015 | - | $130.02 M(+43.5%) |
| Mar 2015 | - | $90.60 M(-9.0%) |
| Dec 2014 | $99.51 M(+60.7%) | $99.51 M(+110.2%) |
| Sept 2014 | - | $47.34 M(+0.2%) |
| June 2014 | - | $47.23 M(+44.5%) |
| Mar 2014 | - | $32.69 M(-47.2%) |
| Dec 2013 | $61.94 M(+59.1%) | $61.94 M(+98.6%) |
| Sept 2013 | - | $31.19 M(+27.8%) |
| June 2013 | - | $24.42 M(-1.3%) |
| Mar 2013 | - | $24.73 M(-36.5%) |
| Dec 2012 | $38.93 M(+40.4%) | $38.93 M(+77.4%) |
| Sept 2012 | - | $21.94 M(-14.5%) |
| June 2012 | - | $25.67 M(+1.1%) |
| Mar 2012 | - | $25.39 M(-8.5%) |
| Dec 2011 | $27.74 M(+77.9%) | $27.74 M(+60.2%) |
| Sept 2011 | - | $17.31 M(-33.3%) |
| June 2011 | - | $25.95 M(+60.8%) |
| Mar 2011 | - | $16.15 M(+3.6%) |
| Dec 2010 | $15.59 M(+148.7%) | $15.59 M(+19.6%) |
| June 2009 | - | $13.03 M(-26.7%) |
| Mar 2009 | - | $17.78 M(+183.6%) |
| Dec 2008 | $6.27 M(-22.9%) | $6.27 M(-52.5%) |
| Sept 2008 | - | $13.19 M(+26.4%) |
| June 2008 | - | $10.44 M(+10.1%) |
| Mar 2008 | - | $9.47 M(+16.6%) |
| Dec 2007 | $8.13 M | $8.13 M(+52.5%) |
| Sept 2007 | - | $5.33 M(-71.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2007 | - | $18.55 M(+286.0%) |
| Mar 2007 | - | $4.80 M(-77.6%) |
| Dec 2006 | $21.47 M(+410.8%) | $21.47 M(+487.1%) |
| Sept 2006 | - | $3.66 M(+28.8%) |
| June 2006 | - | $2.84 M(-24.4%) |
| Mar 2006 | - | $3.76 M(-10.6%) |
| Dec 2005 | $4.20 M(-77.7%) | $4.20 M(-79.6%) |
| Sept 2005 | - | $20.60 M(+20.9%) |
| June 2005 | - | $17.04 M(-2.4%) |
| Mar 2005 | - | $17.47 M(-7.4%) |
| Dec 2004 | $18.87 M(-0.3%) | $18.87 M(-7.0%) |
| Sept 2004 | - | $20.28 M(+28.8%) |
| June 2004 | - | $15.74 M(-16.9%) |
| Mar 2004 | - | $18.95 M(+0.1%) |
| Dec 2003 | $18.93 M(-37.5%) | $18.93 M(-9.7%) |
| Sept 2003 | - | $20.97 M(+49.3%) |
| June 2003 | - | $14.04 M(-44.3%) |
| Mar 2003 | - | $25.20 M(-16.9%) |
| Dec 2002 | $30.31 M(+104.4%) | $30.31 M(+24.3%) |
| Sept 2002 | - | $24.38 M(+44.0%) |
| June 2002 | - | $16.93 M(-0.8%) |
| Mar 2002 | - | $17.07 M(+15.1%) |
| Dec 2001 | $14.83 M(+57.0%) | $14.83 M(+46.5%) |
| Sept 2001 | - | $10.12 M(+21.9%) |
| June 2001 | - | $8.30 M(-11.7%) |
| Mar 2001 | - | $9.40 M(-0.4%) |
| Dec 2000 | $9.45 M(+43.1%) | $9.45 M(+17.8%) |
| Sept 2000 | - | $8.02 M(+5.0%) |
| June 2000 | - | $7.64 M(+10.3%) |
| Mar 2000 | - | $6.92 M(+4.9%) |
| Dec 1999 | $6.60 M(+17.9%) | $6.60 M(+46.7%) |
| Sept 1999 | - | $4.50 M(-8.2%) |
| June 1999 | - | $4.90 M(-18.3%) |
| Mar 1999 | - | $6.00 M(+7.1%) |
| Dec 1998 | $5.60 M(+19.1%) | $5.60 M(+27.3%) |
| Sept 1998 | - | $4.40 M(-13.7%) |
| June 1998 | - | $5.10 M(+37.8%) |
| Mar 1998 | - | $3.70 M(-21.3%) |
| Dec 1997 | $4.70 M(+6.8%) | $4.70 M(+14.6%) |
| Sept 1997 | - | $4.10 M(-19.6%) |
| June 1997 | - | $5.10 M(+50.0%) |
| Mar 1997 | - | $3.40 M(-22.7%) |
| Dec 1996 | $4.40 M(-30.2%) | $4.40 M(+4.8%) |
| Sept 1996 | - | $4.20 M(0.0%) |
| June 1996 | - | $4.20 M(-2.3%) |
| Mar 1996 | - | $4.30 M(-31.7%) |
| Dec 1995 | $6.30 M(+26.0%) | $6.30 M(+46.5%) |
| Sept 1995 | - | $4.30 M(-6.5%) |
| June 1995 | - | $4.60 M(+24.3%) |
| Mar 1995 | - | $3.70 M(-26.0%) |
| Dec 1994 | $5.00 M(-51.5%) | $5.00 M(+19.0%) |
| Sept 1994 | - | $4.20 M(-34.4%) |
| June 1994 | - | $6.40 M(+6.7%) |
| Mar 1994 | - | $6.00 M(-41.7%) |
| Dec 1993 | $10.30 M(+312.0%) | $10.30 M(+53.7%) |
| Sept 1993 | - | $6.70 M(+28.8%) |
| June 1993 | - | $5.20 M(+73.3%) |
| Mar 1993 | - | $3.00 M(+20.0%) |
| Dec 1992 | $2.50 M(+56.3%) | $2.50 M(+31.6%) |
| June 1992 | - | $1.90 M(0.0%) |
| Mar 1992 | - | $1.90 M(+18.8%) |
| Dec 1991 | $1.60 M | $1.60 M(+220.0%) |
| Sept 1991 | - | $500.00 K(-37.5%) |
| June 1991 | - | $800.00 K |
FAQ
- What is Regeneron Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual accounts payable year-on-year change?
- What is Regeneron Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly accounts payable year-on-year change?
What is Regeneron Pharmaceuticals annual accounts payable?
The current annual accounts payable of REGN is $606.60 M
What is the all time high annual accounts payable for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual accounts payable is $606.60 M
What is Regeneron Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, REGN annual accounts payable has changed by +$17.40 M (+2.95%)
What is Regeneron Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of REGN is $497.30 M
What is the all time high quarterly accounts payable for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly accounts payable is $671.30 M
What is Regeneron Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, REGN quarterly accounts payable has changed by -$39.30 M (-7.32%)